Pharmacokinetics in children
Pediatric pharmacokinetic studies in children have not been conducted.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Hypertension |
- Oral
-
1 year
up to
6 years
- Initial dose:
(Bisoprolol fumarate)
0.05
mg/kg/day
in 1
dose
- Maintenance dose:
slowly titrate dose based on effect to max
10
mg/day
in 1
dose
-
6 years
up to
18 years
- Initial dose:
(Bisoprolol fumarate)
2.5
mg/day
in 1
dose
- Maintenance dose:
slowly titrate dose based on effect to max
10
mg/day
in 1
dose
|
| Cardiac failure |
- Oral
-
6 years
up to
18 years
-
1 year
up to
6 years
|
| Hypoplastic left heart syndrome |
- Oral
-
Term neonate
- Initial dose:
(Bisoprolol fumarate)
0.05
mg/kg/day
in 1
dose
- Maintenance dose:
titrate dose based on effect (heart rate guided) tot max
0.2
mg/kg/day
in 1
dose
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
BETA BLOCKING AGENTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Beta blocking agents, non-selective |
|
|
|
C07AA05
|
|
|
|
C07AA07
|
| Beta blocking agents, selective |
|
|
|
C07AB03
|
|
|
|
C07AB09
|
|
|
|
C07AB02
|
| Alpha and beta blocking agents |
|
|
|
C07AG02
|
|
|
|
C07AG01
|
References
-
MIenert T. et al., Cardiovascular Drug Therapy during Interstage After Hybrid Approach: A Single-Center Experience in 51 Newborns with Hypoplastic Left Heart., Paediatr Drugs, 2021, 23(2), 195-202
-
Sorof JM, et al., Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial., Pediatr Nephrol., 2002, 17(5), 345-50
-
Chaturvedi S, et al, Pharmacological interventions for hypertension in children., Cochrane Database Syst Rev., 2014, (2), CD008117.
-
Bourke JP, et al., Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial., Neurol Clin Pract., 2021, 11(5), e661-e8.
Therapeutic Drug Monitoring
Overdose